{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:15:12Z","timestamp":1779916512876,"version":"3.53.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","award":["P15593"],"award-info":[{"award-number":["P15593"]}],"id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40256-018-00314-4","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T03:04:21Z","timestamp":1553742261000},"page":"313-323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6292-997X","authenticated-orcid":false,"given":"Neil R.","family":"Poulter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamon","family":"Dolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Whitehouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Sever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"key":"314_CR1","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/S0140-6736(16)31679-8","volume":"388","author":"GBD 2015 Risk Factors Collaborators","year":"2016","unstructured":"GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1659\u2013724.","journal-title":"Lancet"},{"key":"314_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/01.HYP.0000103630.72812.10","volume":"43","author":"K Wolf-Maier","year":"2004","unstructured":"Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control on five European countries, Canada, and the United States. Hypertension. 2004;43:10\u20137.","journal-title":"Hypertension"},{"key":"314_CR3","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jama.2013.184182","volume":"310","author":"CK Chow","year":"2013","unstructured":"Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310:959\u201368.","journal-title":"JAMA"},{"key":"314_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1161\/HYPERTENSIONAHA.108.125617","volume":"53","author":"E Falaschetti","year":"2009","unstructured":"Falaschetti E, Chaudhury M, Mindell J, Poulter NR. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension. 2009;53:480\u20136.","journal-title":"Hypertension"},{"key":"314_CR5","doi-asserted-by":"crossref","unstructured":"Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG et al. Clinical practice guidelines for the management of hypertension in the community. A statement by the American Society of Hypertension and the International Society of Hypertension. Hypertension. 2014; 32:3-15.","DOI":"10.1097\/HJH.0000000000000065"},{"key":"314_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cjca.2016.02.066","volume":"32","author":"AA Leung","year":"2016","unstructured":"Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, et al. Hypertension Canada\u2019s 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2016;32:569\u201388.","journal-title":"Can J Cardiol"},{"key":"314_CR7","doi-asserted-by":"crossref","unstructured":"Mancia G, Fagard R, Narkiewicz K, Red\u00f3n J, Zanchetti A, B\u00f6hm M et al. ESH\/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension. 2013; 31:1281\u20131357.","DOI":"10.1097\/01.hjh.0000431740.32696.cc"},{"key":"314_CR8","unstructured":"NICE Guidelines in Hypertension 2011: Clinical management of primary hypertension in adults. \n                    https:\/\/www.nice.org.uk\/guidance\/cg127\/resources\/hypertension-in-adults-diagnosis-and-management-pdf-35109454941637\n                    \n                  . Accessed 2 June 2017."},{"key":"314_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/sj.jhh.1001683","volume":"18","author":"B Williams","year":"2004","unstructured":"Williams B, Poulter N, Brown M, Davies M, McInnnes G, Potter J, Sever P, Thom S. Guidelines for the management of hypertension: report of the fourth working party of the British Hypertension Society 2004\u2014BHS IV. J Hum Hypertens. 2004;18:139\u201385.","journal-title":"J Hum Hypertens."},{"key":"314_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. JACC. 2018;71:127\u2013248.","journal-title":"JACC."},{"key":"314_CR11","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"314_CR12","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/HYPERTENSIONAHA.112.194167","volume":"59","author":"BM Egan","year":"2012","unstructured":"Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59:1124\u201331.","journal-title":"Hypertension"},{"key":"314_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1161\/HYPERTENSIONAHA.109.139816","volume":"55","author":"AK Gupta","year":"2010","unstructured":"Gupta AK, Arshad A, Poulter NP. Compliance, safety and effectiveness of fixed dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399\u2013407.","journal-title":"Hypertension"},{"key":"314_CR14","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3111\/13696998.2011.596873","volume":"14","author":"O Baser","year":"2011","unstructured":"Baser O, Andrews LM, Wang L, Xie L. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan\/amlodipine single-pill combination versus angiotensin receptor blocker\/calcium channel blocker free-combination therapy. J Med Econ. 2011;14:576\u201383.","journal-title":"J Med Econ."},{"key":"314_CR15","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","unstructured":"PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033\u201341.","journal-title":"Lancet"},{"key":"314_CR16","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022\u201331.","journal-title":"Lancet"},{"key":"314_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"36","author":"B Dahlof","year":"2005","unstructured":"Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;36:895\u2013906.","journal-title":"Lancet"},{"key":"314_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF03256570","volume":"9","author":"VK Bahl","year":"2009","unstructured":"Bahl VK, Jadhav UM, Thacker HP. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter Study. Am J Cardiovasc Drugs. 2009;9:135\u201342.","journal-title":"Am J Cardiovasc Drugs."},{"key":"314_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jash.2013.01.006","volume":"7","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Ly C, Yannoutsos A, Agnoletti D, Mourad JJ, Safar ME, et al. Effect of a fixed combination of Perindopril and Amlodipine on blood pressure control in 6256 patients with not-at-goal hypertension: the AVANT\u2019AGE study. J Am Soc Hypertens. 2013;7:163\u20139.","journal-title":"J Am Soc Hypertens."},{"key":"314_CR20","unstructured":"Health Products Regulatory Authority. Summary of product characteristics, Viacoram 3.5\u00a0mg\/2.5\u00a0mg. \n                    https:\/\/www.hpra.ie\/img\/uploaded\/swedocuments\/LicenseSPC_PA0568-027-001_23052015115329.pdf\n                    \n                  . Accessed 2 June 2017."},{"key":"314_CR21","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of hypertension. London, 18 November 2010. EMA\/238\/1995\/Rev. 3."},{"key":"314_CR22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(10)60308-X","volume":"375","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, Howard SC, Dolan E, O\u2019Brien E, Dobson JE, Dahlof B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895\u2013905.","journal-title":"Lancet."},{"key":"314_CR23","unstructured":"EuroQol. EQ5D Questionnaire. \n                    http:\/\/www.euroqol.org\n                    \n                  . Accessed 2 June 2017."},{"key":"314_CR24","unstructured":"International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. \n                    https:\/\/www.idf.org\/e-library\/consensus-statements\/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome\n                    \n                  . Accessed 2 June 2017."},{"key":"314_CR25","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1016\/S0140-6736(14)60688-7","volume":"383","author":"E Falaschetti","year":"2014","unstructured":"Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension management in England: a serial cross-sectional study from 1994\u20132011. Lancet. 2014;383:1912\u20139.","journal-title":"Lancet"},{"key":"314_CR26","first-page":"312320","volume":"377","author":"MJ Brown","year":"2011","unstructured":"Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011;377:312320.","journal-title":"Lancet"},{"key":"314_CR27","doi-asserted-by":"crossref","unstructured":"ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, remipril, or both in patients at high risk of vascular events. N Engl J Med. 2008; 358:1547\u201359.","DOI":"10.1056\/NEJMoa0801317"},{"key":"314_CR28","doi-asserted-by":"crossref","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahl\u00f6f B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydroclorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359:2417\u201328.","DOI":"10.1056\/NEJMoa0806182"},{"key":"314_CR29","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jacc.2010.07.053","volume":"57","author":"FH Messerli","year":"2011","unstructured":"Messerli FH, Makani H, Benjo A, Romero J, Alviar C, Bangalore S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol. 2011;57:590\u2013600.","journal-title":"J Am Coll Cardiol"},{"key":"314_CR30","doi-asserted-by":"crossref","unstructured":"Rothwell PM, Howard SC, Dolan E, O\u2019Brien E, Dobson JE, Poulter NR, Sever PS on behalf of the ASCOT-BPLA and MRC Trial Investigators. Effects of \u03b2-blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9(5):469\u2013480.","DOI":"10.1016\/S1474-4422(10)70066-1"},{"key":"314_CR31","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S0140-6736(10)60309-1","volume":"375","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, et al. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375:938\u201348.","journal-title":"Lancet"},{"key":"314_CR32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/HJH.0000000000000409","volume":"33","author":"G Mancia","year":"2015","unstructured":"Mancia G, Asmar R, Amodeo C, Mourad JJ, Taddei S, Gamba MA, Chazova IE, Puig JG. Comparison of single-pill strategies first line in hypertension: perindopril\/amlodipine versus valsartan\/amlodipine. J Hypertens. 2015;33:401\u201311.","journal-title":"J Hypertens"},{"key":"314_CR33","doi-asserted-by":"crossref","unstructured":"Laurent S, Parati G, Chazova I, Sirenko Y, Erglis A, Laucevicius A, Farsang C. Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5\u200amg\/amlodipine 2.5\u200amg as a first-step treatment in hypertension. J Hypertens. 2015; 33:653\u2013661.","DOI":"10.1097\/HJH.0000000000000440"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-00314-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-018-00314-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-00314-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:27:44Z","timestamp":1585268864000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-018-00314-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["314"],"URL":"https:\/\/doi.org\/10.1007\/s40256-018-00314-4","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,28]]},"assertion":[{"value":"28 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Servier. Medical writing and editorial support, under the guidance of the authors, was provided by John Plant (Servier).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Neil Poulter has received financial support from several pharmaceutical companies that manufacture BP-lowering agents, for consultancy (Servier), research projects and staff (Pfizer, Servier), and arranging and speaking at education meetings (Astra Zeneca, Lri Therapharma, Napi, Servier, and Pfizer). He holds no stocks or shares in any such companies. In the last 3\u00a0years, Ajay Gupta has received financial support to attend a conference and an honorarium for a presentation from Servier, but these funds were for activities unrelated to this manuscript. During the conduct of this study, he was part of an independent safety and adjudication committee and received consulting fees for that work. Andrew Whitehouse has claimed travel expenses during the conduct of the study to attend study sites and the funder\u2019s offices. Eamon Dolan, Eoin O\u2019Brien, and Peter Sever have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of national research committees and with the Helsinki declaration.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}